CMB-100

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCMB-100
Drug Alias Namemesenchymal stem cell-based therapy (Wibi+Works)proimunocelMSC1 (Wibi+Works)CMB-100
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCommence Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCommence Bio Inc
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A